Profile picture of Santarus

Santarus

San Diego, CA
2 staff members
2.5 191 Reviews
Company Profile

Santarus is a bit controlling, but in this case it's okay. Santarus' flagship drug Glumetza improves glycemic control for type 2 diabetes patients and is marketed through a partnership with Depomed. It markets a similar drug, Cycloset, also to improve glycemic control for type 2 diabetes, through a distribution and license agreement with S2 Therapeutics and Veroscience. Santarus' lead product used to be Zegerid, a modified version of omeprazole, the proton pump inhibitor found in AstraZeneca's best-selling Prilosec for heartburn. But when Zegerid's patent ran out and its sales dropped, Santarus moved on to more fruitful ground. Other candidates include treatments for ulcerative colitis and angioedema.

Company size

201 to 500

Type

Company - Public

Revenue

$100 to $500 million (USD) per year

Industry

Biotech & Pharmaceuticals

Competitors

Procter & Gamble, Novartis, AstraZeneca

Founded

1996

Staff Members
avatar
CEO
1.0
Worked since Tuesday, Dec 06 2022
People Also Viewed